Friday's Underperforming Sectors: General Contractors & Builders, Healthcare Providers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2025
0mins
Should l Buy AGL?
Source: NASDAQ.COM
Market Performance: Hospital and medical practitioners' shares are lagging the market, down approximately 0.2% overall.
Key Contributors: Ardent Health and Agilon Health are leading the decline, with shares down 2.8% and 1.8%, respectively.
Sector Laggards: The report also mentions general contractors and builders as part of the sector laggards on the same day.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 8.035
Low
0.88
Averages
0.88
High
0.88
Current: 8.035
Low
0.88
Averages
0.88
High
0.88
About AGL
agilon health, inc. is a healthcare company. The Company operates a Medicare-centric, capitated line of business. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing monthly payments to manage the total healthcare needs of its physician partners attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform supports the transition to a Total Care Model with technology, people, process and capital.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agilon Health Implements 1-for-25 Reverse Stock Split to Regain NYSE Compliance
- Reverse Stock Split: Agilon Health announced a 1-for-25 reverse stock split effective March 30, 2026, to comply with NYSE minimum bid price requirements, with trading on a split-adjusted basis starting March 31, aiming to lift its share price for continued listing compliance.
- Shareholder Approval: At a special meeting on March 17, shareholders approved the reverse split proposal ranging from 1-for-5 to 1-for-25, with the board opting for the 1-for-25 ratio, reflecting the company's responsiveness to shareholder input.
- Reduction in Outstanding Shares: Following the reverse split, Agilon Health's outstanding shares will decrease from approximately 415 million to about 16.6 million, which is expected to enhance the stock's marketability and liquidity, potentially attracting more investor interest.
- Value-Based Care Model: Agilon Health partners with physician groups and health systems to support a value-based care model for senior patients, providing technology, capital, and operational support, although the market remains cautious about its investment potential, it is still viewed as a stock with upside potential.
See More
Major U.S. Indices Decline as Inflation Exceeds Expectations
- Inflation Impact: On Wednesday, major U.S. indices closed lower after two days of gains, with the S&P 500 down 1.4%, the Nasdaq Composite down 1.5%, and the Dow Jones Industrial Average down 1.6%, reflecting investor concerns over hotter-than-expected wholesale inflation data.
- Micron Technology Earnings: Despite Micron Technology (MU) reporting adjusted earnings of $12.20 per share and revenue of $23.86 billion, both significantly exceeding Wall Street expectations with a 196.4% year-over-year increase, its shares fell approximately 3.5% in after-hours trading, indicating market caution regarding future performance.
- Five Below Sales Surge: Five Below (FIVE) saw its shares rise in after-hours trading following a 24.5% year-over-year sales increase to $1.73 billion in fiscal Q4, well above the 13.7% consensus estimate, with comparable sales jumping 15.3%, showcasing strong consumer demand and market performance.
- agilon health Stock Split: Agilon health (AGL) announced a 1-for-25 reverse stock split effective March 30, 2026, aimed at raising its share price above $1.00 to meet NYSE listing requirements, thereby improving stock liquidity and marketability to attract broader investor interest.
See More
Halper Sadeh LLC Investigates Agilon Health Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact the firm to discuss their rights and options at no cost, aiming to ensure shareholders can enforce their rights within a limited timeframe.
- Corporate Governance Reform: The investigation focuses on whether certain officers and directors of Agilon Health, Inc. (NYSE:AGL) breached their fiduciary duties, allowing long-term shareholders to seek governance reforms and potential fund recovery.
- Enhancing Transparency: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, creating a more transparent, accountable, and effectively managed organization, ultimately enhancing shareholder value.
- Legal Support and Success Stories: Halper Sadeh LLC represents investors globally against securities fraud and corporate misconduct, with attorneys instrumental in implementing corporate reforms and recovering millions for defrauded investors.
See More
Kuehn Law Investigates Agilon Health Executives' Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Agilon Health, Inc. breached their fiduciary duties to shareholders, with allegations of intentional misrepresentation in a federal securities lawsuit.
- Misleading Financial Guidance: The lawsuit claims that Agilon Health's guidance for 2025 was recklessly issued, as executives knew or should have known that the targets were unattainable, negatively impacting the company's future financial performance.
- Exaggerated Risk Management: It is also alleged that the immediate positive financial impact from strategic actions taken by Agilon to mitigate risks was materially overstated, leading to significant false or misleading statements about the company's business and operations during relevant periods.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased AGL stock prior to February 26, 2025, to contact their attorney immediately to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining the integrity and fairness of financial markets.
See More
Agilon Health Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Agilon Health for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and August 4, 2025, with a deadline to contact the firm by March 2, 2026.
- False Statements Allegation: The complaint alleges that Agilon made false and misleading statements regarding its 2026 guidance, which was beyond its capabilities, and overstated the effectiveness of its strategic actions to mitigate risks, resulting in investor losses when the truth emerged.
- Legal Representation Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Advocacy: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, urging affected investors to join the lawsuit to seek compensation for their losses, highlighting its commitment to protecting investor rights globally.
See More
Class Action Lawsuit Filed Against Agilon Health, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. announces a class action lawsuit against Agilon Health, Inc. on behalf of investors who purchased securities between February 26, 2025, and August 4, 2025, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Allegation Details: The lawsuit claims that Agilon's management issued unrealistic 2025 financial guidance despite being aware of significant industry challenges and overstated the immediate financial benefits from strategic actions, misleading investors about the company's business prospects.
- Investor Rights: Affected investors must apply by March 2, 2026, to be appointed as lead plaintiff in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for more information.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, with extensive litigation experience and a nationwide practice.
See More
Agilon Health Implements 1-for-25 Reverse Stock Split to Regain NYSE Compliance
- Reverse Stock Split: Agilon Health announced a 1-for-25 reverse stock split effective March 30, 2026, to comply with NYSE minimum bid price requirements, with trading on a split-adjusted basis starting March 31, aiming to lift its share price for continued listing compliance.
- Shareholder Approval: At a special meeting on March 17, shareholders approved the reverse split proposal ranging from 1-for-5 to 1-for-25, with the board opting for the 1-for-25 ratio, reflecting the company's responsiveness to shareholder input.
- Reduction in Outstanding Shares: Following the reverse split, Agilon Health's outstanding shares will decrease from approximately 415 million to about 16.6 million, which is expected to enhance the stock's marketability and liquidity, potentially attracting more investor interest.
- Value-Based Care Model: Agilon Health partners with physician groups and health systems to support a value-based care model for senior patients, providing technology, capital, and operational support, although the market remains cautious about its investment potential, it is still viewed as a stock with upside potential.
See More
Major U.S. Indices Decline as Inflation Exceeds Expectations
- Inflation Impact: On Wednesday, major U.S. indices closed lower after two days of gains, with the S&P 500 down 1.4%, the Nasdaq Composite down 1.5%, and the Dow Jones Industrial Average down 1.6%, reflecting investor concerns over hotter-than-expected wholesale inflation data.
- Micron Technology Earnings: Despite Micron Technology (MU) reporting adjusted earnings of $12.20 per share and revenue of $23.86 billion, both significantly exceeding Wall Street expectations with a 196.4% year-over-year increase, its shares fell approximately 3.5% in after-hours trading, indicating market caution regarding future performance.
- Five Below Sales Surge: Five Below (FIVE) saw its shares rise in after-hours trading following a 24.5% year-over-year sales increase to $1.73 billion in fiscal Q4, well above the 13.7% consensus estimate, with comparable sales jumping 15.3%, showcasing strong consumer demand and market performance.
- agilon health Stock Split: Agilon health (AGL) announced a 1-for-25 reverse stock split effective March 30, 2026, aimed at raising its share price above $1.00 to meet NYSE listing requirements, thereby improving stock liquidity and marketability to attract broader investor interest.
See More
Halper Sadeh LLC Investigates Agilon Health Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact the firm to discuss their rights and options at no cost, aiming to ensure shareholders can enforce their rights within a limited timeframe.
- Corporate Governance Reform: The investigation focuses on whether certain officers and directors of Agilon Health, Inc. (NYSE:AGL) breached their fiduciary duties, allowing long-term shareholders to seek governance reforms and potential fund recovery.
- Enhancing Transparency: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, creating a more transparent, accountable, and effectively managed organization, ultimately enhancing shareholder value.
- Legal Support and Success Stories: Halper Sadeh LLC represents investors globally against securities fraud and corporate misconduct, with attorneys instrumental in implementing corporate reforms and recovering millions for defrauded investors.
See More
Kuehn Law Investigates Agilon Health Executives' Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Agilon Health, Inc. breached their fiduciary duties to shareholders, with allegations of intentional misrepresentation in a federal securities lawsuit.
- Misleading Financial Guidance: The lawsuit claims that Agilon Health's guidance for 2025 was recklessly issued, as executives knew or should have known that the targets were unattainable, negatively impacting the company's future financial performance.
- Exaggerated Risk Management: It is also alleged that the immediate positive financial impact from strategic actions taken by Agilon to mitigate risks was materially overstated, leading to significant false or misleading statements about the company's business and operations during relevant periods.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased AGL stock prior to February 26, 2025, to contact their attorney immediately to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining the integrity and fairness of financial markets.
See More
Agilon Health Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Agilon Health for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and August 4, 2025, with a deadline to contact the firm by March 2, 2026.
- False Statements Allegation: The complaint alleges that Agilon made false and misleading statements regarding its 2026 guidance, which was beyond its capabilities, and overstated the effectiveness of its strategic actions to mitigate risks, resulting in investor losses when the truth emerged.
- Legal Representation Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their rights to recover losses.
- Investor Rights Advocacy: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, urging affected investors to join the lawsuit to seek compensation for their losses, highlighting its commitment to protecting investor rights globally.
See More
Class Action Lawsuit Filed Against Agilon Health, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. announces a class action lawsuit against Agilon Health, Inc. on behalf of investors who purchased securities between February 26, 2025, and August 4, 2025, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Allegation Details: The lawsuit claims that Agilon's management issued unrealistic 2025 financial guidance despite being aware of significant industry challenges and overstated the immediate financial benefits from strategic actions, misleading investors about the company's business prospects.
- Investor Rights: Affected investors must apply by March 2, 2026, to be appointed as lead plaintiff in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations and encouraging investors to reach out for more information.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, with extensive litigation experience and a nationwide practice.
See More
